目錄:MedChemExpress LLC>>生化試劑>> JI-101 | MCE
CAS | 900573-88-8 | 純度 | 99.43% |
---|---|---|---|
分子量 | 466.33 | 分子式 | C??H??BrN?O? |
供貨周期 | 現貨 | 規格 | 5 mg |
貨號 | HY-16265 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 900573-88-8
產品活性:JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.
研究領域:Protein Tyrosine Kinase/RTK
作用靶點:Ephrin Receptor | PDGFR | VEGFR
In Vitro: JI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95 across the tested species liver microsomes. The % metabolized is relatively higher in mice liver microsomes followed by dog, human and rat liver microsomes.
In Vivo: JI-101excreted through bile along with its mono- and di-hydroxy metabolites. Following oral administration, JI-101 is rapidly absorbed, reaching Cmax within 2?h. The t1/2 of JI-101 with intravenous and oral route is found to be 1.75±0.79 and 2.66±0.13?h, respectively. The Cl and Vd by intravenous route for JI-101 are found to be 13.0±2.62?mL/min/kg and 2.11±1.42?L/kg, respectively. The tissue distribution of JI-101 is extensive with rapid and preferred uptake into lung tissue. Overall, the oral bioavailability of JI-101 is 55% and the primary route of elimination for JI-101 is feces.
相關產品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-Cardiovascular Disease Compound Library | Orally Active Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | 5α-Hydroxycostic acid | GW806742X hydrochloride | Sennoside B | Sorafenib-d4 | 123C4 | BMS-690514 | VEGFR-2-IN-6 | PROTAC VEGFR-2 degrader-1 | Flumatinib mesylate | Multi-kinase-IN-2 | Eph inhibitor 2 | Sorafenib Tosylate | K00546 | c-Met-IN-11 | PP58 | VEGFR-2-IN-29 | Threo-Chloramphenicol-d6 | Foretinib | CT52923 | ZM323881 hydrochloride | ODM-203 | Taurocholic acid sodium | VEGFR-2/DHFR-IN-2 | ENMD-2076 Tartrate | Albendazole | SU5408 | R1530 | AZD2932 | Toceranib phosphate | EGFR-IN-57
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。